3,4-Dihydroxybenzylamine hydrobromide

SKU: orb1940839

Description

3,4-Dihydroxybenzylamine hydrobromide inhibits DNA polymerase activity in melanoma cells and displays growth inhibitory activity in melanoma cell lines with varying degrees of tyrosinase activity.(In Vitro):3,4-Dihydroxybenzylamine hydrobromide (1 μM-10 mM; 48 hours) inhibits the growth of all melanoma cell lines (IC50 = 100 μM) and the SK-MELB cell line (IC50 = 122 μM). The IC50 values are 30, 84,90, and 68 μM for Human SK-MEL-30, SK-MEL-2, SK-MEL-3,RPMI-7951 cells, respectively. 3,4-Dihydroxybenzylamine hydrobromide (1 μM-10 mM; 48 hours) cytotoxicity in SK-MEL-2 and SK-MEL-28 cell lines can be enhanced by application of buthionine sulfoximine (BSO). BSO treatment sensitizes marginally pigmented cells to the effects of 3,4-DHBA, and the presence of decreses IC50 values of 3,4-DHBA by 127% in the SK-MEL-28 cell line and by 148% in the SK-MEL-2 cell line. 3,4-Dihydroxybenzylamine hydrobromide exhibits IC50values of 10, 25, 67, and 184 μM for S91A, S91B, L1210, and SCC-25 cells, respectively.(In Vivo):3,4-Dihydroxybenzylamine hydrobromide (200, 400, 600 and 800 mg/kg; i.p.; 21 days) has different effects at different doses, the median life-span are 17, 24.5, 26, 29 and 25 days respectively. 3,4-Dihydroxybenzylamine hydrobromide (1000 mg/kg; i.p.; 7 days) has the least toxic effect in non-tumor-bearing B6D2F1 mice,and mice is tolerated at this dose.

Key Properties

• CAS Number: 16290-26-9
• MW: 220.066
• Purity: >98% (HPLC)
• Formula: C₇H₁₀BrNO₂
• SMILES: Br.NCc1ccc(O)c(O)c1
• Target: P450| protein tyrosine phosphatase(PTP)| SETD8
• Solubility: In Vitro: DMSO : 83.33 mg/mL (378.67 mM)

Bioactivity

• In Vivo:
  3, 4-Dihydroxybenzylamine hydrobromide (intraperitoneal injection; 1000 mg/kg; 7 days) has the least toxic effect in non-tumor-bearing B6D2F1 mice, and mice is tolerated at this dose. 3, 4-Dihydroxybenzylamine hydrobromide (intraperitoneal injection; 200-800 mg/kg; 21 days) has different effects at different doses, the median life-span are 17, 24.5, 26, 29 and 25 days for 0 mg/kg, 200 mg/kg, 400 mg/kg, 600 mg/kg, and 800 mg/kg, respectively. Animal model: C57BL/6 mice withB6D2F1 cells. Dosage: 200 mg/kg, 400 mg/kg, 600 mg/kg, and 800 mg/kg. Administration: Intraperitoneal injection. Result: Exhibited increased life-span of 44%, 46%, 70% and 50% for 200 mg/kg, 400 mg/kg, 600 mg/kg, and 800 mg/kg, respectively.
  Read more...
• In Vitro:
  3, 4-Dihydroxybenzylamine hydrobromide (1 μM-10 mM; 48 hours) inhibits the growth of all melanoma cell lines with an IC50 of 100 μM, while the SK-MELB cell line exhibits an IC50 of 122 μM. The IC50 values are 30, 84, 90, and 68 μM for Human SK-MEL-30, SK-MEL-2, SK-MEL-3, RPMI-7951 cells, respectively. It exhibits IC50values of 10, 25, 67, and 184 μM for S91A, S91B, L1210, and SCC-25 cells, respectively.3, 4-Dihydroxybenzylamine hydrobromide (1 μM-10 mM; 48 hours) cytotoxicity in SK-MEL-2 and SK-MEL-28 cell lines can be enhanced by application of buthionine sulfoximine (BSO). BSO treatment sensitizes marginally pigmented cells to the effects of 3, 4-DHBA, and the presence of decreses IC50 values of 3, 4-DHBA by 127% in the SK-MEL-28 cell line and by 148% in the SK-MEL-2 cell line. Cell Viability Assay Cell line: Human and Murine Melanoma Cell Lines; Non-Melanoma Cell Lines. Concentration: 1 μM-10 mM. Incubation time: 48 hours. Result: Inhibited melanoma cell Lines growth.
  Read more...

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

NSC 263475 hydrobromide

Quick Database Links

Gene Symbol

P450| protein tyrosine phosphatase(PTP)| SETD8